GEMTYLE 1000 Injection: Gemcitabine 1000 mg

Multi-Spectrum Efficacy: A Core Component in Cancer Protocols

The Mechanism: Inhibiting DNA Synthesis and Inducing Apoptosis

Standard of Care in Pancreatic, Lung, and Breast Cancer Management

High-Value Market: Injectable Oncology Demand in India
Secure Your Future: GEMTYLE 100 PCD Pharma Franchise with Monopoly

Home/Products /gemcitabine-1000mg-injection

Gemtyle 1000 Injection

Composition : Gemcitabine 1000mg Injection

Dosage Form : Injection

Packaging Type : Vial

Packaging : 1gm

Price : ₹1/-

Contact For Business Query

GEMTYLE 1000 Injection (Gemcitabine 1000 mg) is a widely used and indispensable cytotoxic chemotherapy agent in modern oncology. Classified as an antimetabolite (a pyrimidine analog), it is crucial for the treatment of several aggressive malignancies, including: Pancreatic Cancer (as a monotherapy or in combination), Non-Small Cell Lung Cancer (NSCLC) (in combination with cisplatin), Ovarian Cancer (in combination with carboplatin), and Metastatic Breast Cancer (in combination with paclitaxel).

Gemcitabine works as a prodrug, converting inside the cancer cell into active metabolites that inhibit DNA synthesis (masked chain termination) and block the enzyme ribonucleotide reductase. This dual action effectively slows or stops the growth and spread of cancer cells.

The demand for high-quality, generic injectable oncology products like Gemcitabine is consistently high, driven by the rising prevalence of cancer globally and the necessity of chemotherapy in standard treatment protocols. This places GEMTYLE 1000 in a high-demand, high-growth market segment. We offer a lucrative PCD Pharma Franchise opportunity with exclusive Monopoly Rights for Gemcitabine 1000 mg, ensuring competitive pricing, quality assurance, and comprehensive promotional support for targeted distribution to hospitals and oncology centers.

Read More

About the Product

GEMTYLE 1000 Injection (Gemcitabine 1000 mg) is a widely used and indispensable cytotoxic chemotherapy agent in modern oncology. Classified as an antimetabolite (a pyrimidine analog), it is crucial for the treatment of several aggressive malignancies, including: Pancreatic Cancer (as a monotherapy or in combination), Non-Small Cell Lung Cancer (NSCLC) (in combination with cisplatin), Ovarian Cancer (in combination with carboplatin), and Metastatic Breast Cancer (in combination with paclitaxel).

Gemcitabine works as a prodrug, converting inside the cancer cell into active metabolites that inhibit DNA synthesis (masked chain termination) and block the enzyme ribonucleotide reductase. This dual action effectively slows or stops the growth and spread of cancer cells.

The demand for high-quality, generic injectable oncology products like Gemcitabine is consistently high, driven by the rising prevalence of cancer globally and the necessity of chemotherapy in standard treatment protocols. This places GEMTYLE 1000 in a high-demand, high-growth market segment. We offer a lucrative PCD Pharma Franchise opportunity with exclusive Monopoly Rights for Gemcitabine 1000 mg, ensuring competitive pricing, quality assurance, and comprehensive promotional support for targeted distribution to hospitals and oncology centers.

May cause headache, muscle pain, nausea, abdominal discomfort, or mild liver enzyme elevation. Rarely, serious muscle problems (myopathy or rhabdomyolysis) may occur.

Primary hypercholesterolemia Mixed dyslipidemia Familial hypercholesterolemia Prevention of cardiovascular disease in high-risk patients

Take under medical supervision, preferably once daily, with or without food. Regular liver function and lipid profile monitoring is advised. Inform your doctor about any muscle pain, weakness, or pre-existing liver/kidney conditions. Avoid excessive alcohol intake.

Store in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation

@2024 | copy rights by Cafoli